AGM
HOWL icon

Alpine Global Management’s Werewolf Therapeutics HOWL Stock Holding History

Alpine Global Management’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-37,551
Closed -$91.6K – 283
2024
Q2 		$91.6K Buy
+37,551
New +$180K 0.02% 420

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Alpine Global Management's HOWL Position: Q3 2024 in Review

Alpine Global Management sold out of Werewolf Therapeutics (HOWL) in Q3 2024, closing a stake of 37,551 shares — an estimated $91.6K sold.

Alpine Global Management first reported a position in HOWL in Q2 2024 and held it in 1 quarter. The position peaked at $91.6K in Q2 2024. 69 funds tracked by Wall St. Rank hold HOWL as of Q3 2024.

  • Alpine Global Management reported no remaining Werewolf Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 37,551 Werewolf Therapeutics shares in Q3 2024, an estimated $91.6K.
  • Alpine Global Management first reported a position in Werewolf Therapeutics in Q2 2024 and held it in 1 quarter.
  • Alpine Global Management's Werewolf Therapeutics position peaked at $91.6K in Q2 2024.
  • 69 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.